"10.1371_journal.pone.0132789","plos one","2015-07-15T00:00:00Z","Masamitsu Konno; Jun Koseki; Koichi Kawamoto; Naohiro Nishida; Hidetoshi Matsui; Dyah Laksmi Dewi; Miyuki Ozaki; Yuko Noguchi; Koshi Mimori; Noriko Gotoh; Nobuhiro Tanuma; Hiroshi Shima; Yuichiro Doki; Masaki Mori; Hideshi Ishii","Department of Frontier Science for Cancer and Chemotherapy, Osaka University Graduate School of Medicine, Osaka, 565–0871, Japan; Department of Cancer Profiling Discovery, Osaka University Graduate School of Medicine, Osaka, 565–0871, Japan; Department of Gastrointestinal Surgery, Osaka University Graduate School of Medicine, Osaka, 565–0871, Japan; Faculty of Science, Kyushu University, Fukuoka, 819–0395, Japan; Kyushu University, Department of Molecular and Surgical Oncology, Tsurumihara 4546, Beppu, Ohita, 874–0838, Japan; Division of Cancer Cell Biology, Cancer Research Institute of Kanazawa University, Kakuma-machi, Kanazawa, 920–1192, Japan; Division of Cancer Chemotherapy, Miyagi Cancer Center Research Institute, Natori, 981–1293, Japan","Conceived and designed the experiments: MK MM HI. Performed the experiments: MK JK KK NN DLD NT HS. Analyzed the data: MK HM KM NG YD. Contributed reagents/materials/analysis tools: MK MO YN. Wrote the paper: MK MM HI.","The authors have the following interests. Institutional endowments were received partially from Taiho Pharmaceutical Co., Ltd. (http://www.taiho.co.jp/english/), Evidence Based Medical (EBM) Research Center (http://ebmrce.co.jp/index.html), Chugai Co., Ltd. (http://www.chugai-pharm.co.jp/english/index.html), Yakult Honsha Co., Ltd. (http://www.yakult.co.jp/english/index.html), and Merck Co., Ltd. There are no patents, products in development or marketed products to declare. This does not alter the authors’ adherence to all the PLOS ONE policies on sharing data and materials, as detailed online in the guide for authors.","2015","07","Masamitsu Konno","MK",15,TRUE,3,7,5,3,TRUE,TRUE,FALSE,0,NA,FALSE
